Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximately 5.8 million Medicare Advantage members.
'The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more people to access this revolutionary, non-invasive colorectal cancer screening test from the comfort of home,' said Jake Orville, Executive Vice President and General Manager, Screening. 'This agreement reflects our shared commitment to removing barriers for patients and advancing earlier detection, when treatment is most effective.'
Cologuard Plus, which launched in March 2025, has received FDA approval, Medicare coverage, and inclusion in the U.S. Preventive Services Task Force guidelines.
About the Cologuard ® and Cologuard Plus ™ tests
Developed in collaboration with Mayo Clinic, the Cologuard ® and Cologuard Plus ™ tests are first-line, noninvasive colorectal cancer (CRC) screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation or time off, and return the kit to the lab for results. It is included in national screening guidelines from the American Cancer Society (2018) and the U.S. Preventive Services Task Force (2021). Since its inception in 2014, Cologuard has been used to screen for more CRC 20 million times.
Building on this success, the FDA-approved Cologuard Plus test raises the performance bar even further and features novel biomarkers, improved laboratory processes, and enhanced sample stability. The Cologuard Plus test is expected to reduce false positives by more than 40% compared to the original Cologuard test, helping minimize unnecessary follow-up colonoscopies. Both tests demonstrate Exact Sciences' commitment to improving CRC screening access and outcomes.
About Exact Sciences
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.
NOTE: Exact Sciences, Cologuard, and Cologuard Plus are trademarks of Exact Sciences Corporation. The Cologuard test and Cologuard Plus test are only available in the U.S.
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding the development and commercialization of the Cologuard Plus test and the performance characteristics and health care benefits of the Cologuard Plus test in a commercial setting, as well as statements regarding the development and commercialization of Exact Sciences' pipeline tests. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Cathie Wood Makes a $69M Bet on Exact Sciences; Sells Palantir, Roblox, and DraftKings
Cathie Wood 's ARK Invest ETFs (exchange-traded funds) made a $69 million bet on Exact Sciences (EXAS) on August 7, marking the largest purchase of the day. The move aligns with Wood's bullish outlook on the biotechnology sector. ARK Invest funds also acquired shares of Airbnb (ABNB), buying 179,197 shares valued at about $21.50 million. Additionally, Wood continued buying shares of CRISPR Therapeutics (CRSP), adding about $3.49 million worth of its stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. On the other hand, the largest sale trade for the day was 1,419,766 shares of Guardant Health (GH) for a huge $71.15 million. Wood also made a surprising sale of 155,217 shares of the online betting platform DraftKings (DKNG), totaling $7.01 million. Moreover, ARK funds sold 38,880 shares of Palantir Technologies (PLTR), amounting to roughly $7.08 million. Wood Pours Millions into Exact Sciences Exact Sciences made its debut in the ARK Invest funds yesterday. The ARK Innovation ETF (ARKK) purchased 1,394,210 shares of Exact Sciences, and the ARK Genomic Revolution ETF (ARKG) bought another 216,512 shares. EXAS stock plunged nearly 8%, marking its 52-week low of $38.81 on August 7. On Wednesday, Exact Sciences reported better-than-expected Q2 results, with a loss narrowing to $0.01 per share. Revenue came in at $811 million, also beating the consensus estimate. Nonetheless, analysts lowered their price target on EXAS stock because they were disappointed with its blood-based colorectal cancer (CRC) test data, which led to the sharp stock price decline. Wood appears to have leveraged the dip in EXAS shares as the company has addressed the issue by signing a deal with competitor Freenome to get access to their blood-based CRC test and pipeline, with FDA approval expected in 2026. Is EXAS Stock a Buy, Hold, or Sell? On TipRanks, EXAS stock has a Strong Buy consensus rating based on 10 Buys and two Hold ratings. The average Exact Sciences price target of $65.75 implies 52.3% upside potential from current levels. Year-to-date, EXAS stock has lost 23.2%.
Business Upturn
2 days ago
- Business Upturn
Lithios Beverages Drives Excitement in NYC with Successful Sampling Events and Times Square Billboard
Photo Courtesy of Lithios Beverages NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Lithios Beverages, an innovator in functional drinks inspired by the energizing potential of lithium, just wrapped up a slate of in-store sampling events across Manhattan and Brooklyn, including at Fairway Gardens Kips Bay, Brooklyn Fair, and 2131 Broadway Street. Led by Alex and Tina Genzer, Lithios Beverages stands out with its unique fusion of flavor and function. Recent samplings saw enthusiastic crowds exploring Lithios Beverages' trio of standout flavors: Berry, Electric Lime, and Orange Mango. 'The feedback has been incredible. Everyone connects with different flavors, and the positive energy at our events was contagious,' said Tina Genzer. The spontaneous excitement around the upcoming launch of Brain Fuel+ Hydration Drink Mix was undeniable, with guests eagerly reserving their spots after learning about its breakthrough formula. Crafted with a mineral-rich base and enhanced by Max Catalyst™ for faster absorption, it delivers 71+ trace minerals from ConcenTrace®, essential electrolytes, Vitamin C, and B12—all in a clean, highly bioavailable format. Science-backed functional ingredients like GeniusPure® Alpha GPC and SalidroPure® Salidrosides support immunity, focus, mental clarity, and natural energy, while helping the body adapt to stress and combat fatigue. Consumers are invited to sign up online ahead of the official launch to receive 10% off their first order. Dustin Elliott, chief brand officer at NNB Nutrition, shared: 'Lithios Beverages captures what NNB stands for—real progress in human performance. GeniusPure® is the most concentrated, clinically researched Alpha GPC, shown to improve cognitive function with just one serving. And SalidroPure™ delivers 99% pure, naturally fermented salidrosides, offering a sustainable alternative to Rhodiola without compromising potency.' The interactive environment saw customers trying creative flavor combinations and brainstorming cocktail ideas, showing buzz building up for Lithios Beverages' next product line. ' The energy was remarkable. People started blending flavors, exchanging recipes, and already envisioning new ways to enjoy our Brain Fuel+ Hydration Drink Mix,' noted co-founder Alexander Genzer. 'Clearly, New Yorkers are looking for hydration that truly supports mind and body.' Lively testimonials continue to flood the company's Instagram (@drinklithiosbeverages). Lithios Beverages also recently made its Times Square debut with stunning billboard spots. This overwhelming support has prompted Fairway Markets to request more sampling events and secure additional inventory. Industry recognition is following suit. Lithios Beverages was spotlighted in GI's recent 'Companies to Watch' report, drawing attention to the broader growth of functional drinks inspired by the dynamic properties associated with lithium. The report, which highlights the functional beverage sector through 2033, can be accessed in the Press and Media area of the Lithios Beverages website. 'We're honored by the excitement and curiosity Lithios Beverages is generating,' said Tina Genzer. 'Just as lithium powers modern technology, Lithios Beverages energizes everyday wellness. Our upcoming Brain Fuel+ Hydration will go even further to meet today's needs for clarity, resilience, and refreshment.' Lithios Beverages is continuing in-store sampling across NYC throughout July, with more events planned for September. It has also opened a round for early-stage investors. For more information, visit or follow @drinklithiosbeverages on Instagram. Contact information:Tina GenzerLithios Beverages Website: [email protected]
Associated Press
2 days ago
- Associated Press
Prolon L-Protein Bar Sets New Standard for Clean, Age-Supportive Nutrition
L-Nutra's newest innovation is a plant-based protein bar formulated to support muscle health and slow age-related nutritional triggers, not just fuel fitness L-Nutra, a global leader in nutrition technology and longevity science, is once again redefining what precision nutrition can do with the launch of the Prolon® L-Protein Bar — a clean, plant-based bar scientifically formulated to provide the perfect balance of amino acids from plant-based sources to support both muscle health and healthy aging, not just workouts. Most protein products today are focused on quantity — more grams, more calories, more bulk. But emerging longevity science shows that too much of the wrong kind of protein can accelerate aging by overstimulating key growth pathways like IGF-1 and mTOR. On the other hand, too little protein — especially in strict vegan diets — may fail to adequately support muscle maintenance and overall strength. Achieving this balance is critical: while excessive protein, particularly from animal sources, may overstimulate pro-aging pathways, too little protein can undermine strength, energy, and overall resilience. The L-Protein Bar is carefully designed to navigate this middle path — delivering the right nutrients, in the right amounts, from the right sources. Now part of the Prolon suite of clinically informed nutrition tools, the L-Protein Bar continues L-Nutra's mission to create smarter everyday nutrition solutions rooted in more than two decades of research. 'If you want to live a long and healthy life, you need to slow the rate of aging every day — and that starts with what you eat,' says Dr. Joseph Antoun, a Harvard- and Johns Hopkins-trained physician and CEO of L-Nutra. 'Protein can accelerate aging if you're choosing the wrong types or the wrong amounts. Our novel L-Protein Bar, rooted in more than 25 years of longevity science, strikes the optimal balance: enough to support muscle strength, but not so much that it speeds up the aging process. And unlike most protein products, there are no hidden ingredients. We pride ourselves on quality ingredients and transparency in how we make our products.' A Protein Bar Built for the Future of Health Formulated by scientists at the USC Longevity Institute, the Prolon L-Protein Bar includes a diverse blend of plant-based proteins (from black beans, chickpeas, and peas) and is fortified with L-methionine, an essential amino acid typically low or missing in vegan diets and other vegan protein supplements. This targeted formulation is designed to maintain a balanced growth factor response while delivering complete protein support for muscle and tissue health. Each bar contains 14 grams of protein, only 170 calories, and is made without added sugars, sugar alcohols, or artificial sweeteners. Instead, it's naturally sweetened with whole dates for a rich flavor and more balanced glycemic response. How Our Protein Bar Redefines the Standard The bar launches in its first flavor, Chocolate Coated, featuring a 100% dark chocolate layer and a rich, satisfying taste. Additional flavors are planned as part of Prolon's expanding Longevity Nutrition platform — a product suite designed to help people integrate clinically-backed, health-supportive nutrition into daily life. The Prolon L-Protein Bar is now available for purchase at About L-Nutra L-Nutra is the global leader in nutri-technology, advancing the discovery, design, and delivery of clinically tested Nutrition for Longevity and Nutrition as Medicine programs. With over 134 issued patents and more than 47 published clinical studies in collaboration with 18 leading universities, L-Nutra's innovations harness the power of plant-based nutrition to support healthy aging, metabolic reset, and cellular rejuvenation. Through its consumer division, Prolon, L-Nutra offers a suite of fasting and longevity-focused products designed to reduce biological age and support whole-body wellness. Its medical division, L-Nutra Health, delivers clinically backed programs aimed at supporting the remission and regression of chronic conditions like type 2 diabetes and metabolic conditions through food-led, lifestyle medicine interventions. Together, these branches reflect L-Nutra's mission to transform what's possible through nutrition and longevity science. To learn more, visit Media Contact Melanie Murphy Richter [email protected] ### SOURCE: L-Nutra Copyright 2025 EZ Newswire
